SOCORRO N1
GenericsSOCORRO N1 is a generic drug manufacturer focused on Cardiovascular.
SOCORRO N1's Key Drugs
SOCORRO N1's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
SOCORRO N1's Recent FDA Approvals
New NDA/BLA approvals for SOCORRO N1 over the last two years — novel drugs only, excluding generics and label supplements.
SOCORRO N1's Therapeutic Areas
SOCORRO N1's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SOCORRO N1's Top Competitors
SOCORRO N1's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SOCORRO N1 Pipeline Snapshot
Active clinical trials for SOCORRO N1 across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2026-08-21
- Latest
- 2026-08-21
- Applications
- 1